Cargando…

S131: A RANDOMISED ASSESSMENT OF THE SEQUENTIAL ADDITION OF THE KINASE INHIBITOR QUIZARTINIB TO INTENSIVE CHEMOTHERAPY IN OLDER ACUTE MYELOID LEUKAEMIA (AML) PATIENTS: RESULTS FROM THE NCRI AML18 TRIAL

Detalles Bibliográficos
Autores principales:	Knapper, Steven, Thomas, Abin, King, Sophie, Thomas, Ian, Gilkes, Amanda, Irwin, Sarah, Sellar, Robert, Green, Simone, Overgaard, Ulrik Malthe, Mehta, Priyanka, Dennis, Mike, Freeman, Sylvie, Russell, Nigel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Oral Sessions
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10428467/ http://dx.doi.org/10.1097/01.HS9.0000967436.08196.70

Ejemplares similares

P503: A RANDOMISED TRIAL OF MOLECULAR MONITORING VERSUS STANDARD CLINICAL CARE IN YOUNGER ADULTS WITH ACUTE MYELOID LEUKAEMIA: RESULTS FROM THE UK NCRI AML17 AND AML19 STUDIES
por: Potter, Nicola, et al.
Publicado: (2023)

Fractionated vs single-dose gemtuzumab ozogamicin with determinants of benefit in older patients with AML: the UK NCRI AML18 trial
por: Freeman, Sylvie D., et al.
Publicado: (2023)

A randomized comparison of CPX-351 and FLAG-Ida in adverse karyotype AML and high-risk MDS: the UK NCRI AML19 trial
por: Othman, Jad, et al.
Publicado: (2023)

S134: FLAG-IDA COMBINED WITH GEMTUZUMAB OZOGAMICIN (GO) REDUCED MRD LEVELS AND IMPROVED OVERALL SURVIVAL IN NPM1MUT AML INDEPENDENT OF FLT3 AND MRD STATUS, RESULTS FROM THE AML19 TRIAL
por: Russell, Nigel, et al.
Publicado: (2023)

P1677: DEFINING KEY QUALITY OF LIFE METRICS IN ACUTE MYELOID LEUKAEMIA AND HIGH RISK MYELODYSPLASTIC SYNDROME PATIENTS ENROLLED IN LARGE-SCALE UK NCRI AML TRIALS
por: Krishnamurthy, Pramila, et al.
Publicado: (2023)

P484: GEMTUZUMAB-BASED INDUCTION CHEMOTHERAPY COMBINED WITH MIDOSTAURIN FOR FLT3 MUTATED AML. UPDATED TOXICITY AND INTERIM SURVIVAL ANALYSIS FROM THE NCRI AML19V2 “MIDOTARG” PILOT TRIAL
por: Russell, Nigel, et al.
Publicado: (2023)

A comparison of FLAG-Ida and daunorubicin combined with clofarabine in high-risk acute myeloid leukaemia: data from the UK NCRI AML17 Trial
por: Burnett, A K, et al.
Publicado: (2018)

S131: CLINICAL IMPLICATIONS OF SECONDARY-AML TYPE MUTATIONS IN PATIENTS WITH DE NOVO ACUTE MYELOID LEUKEMIA
por: Sun, K., et al.
Publicado: (2022)

Addition of the mammalian target of rapamycin inhibitor, everolimus, to consolidation therapy in acute myeloid leukemia: experience from the UK NCRI AML17 trial
por: Burnett, Alan K, et al.
Publicado: (2018)

S130: PRELIMINARY RESULTS OF QUIWI: A DOUBLE BLINDED, RANDOMIZED CLINICAL TRIAL COMPARING STANDARD CHEMOTHERAPY PLUS QUIZARTINIB VERSUS PLACEBO IN ADULT PATIENTS WITH NEWLY DIAGNOSED FLT3-ITD WILD-TYPE AML
por: Montesinos, Pau, et al.
Publicado: (2023)

S132: UPDATED RESULTS OF VEN-A-QUI STUDY: A PHASE 1-2 TRIAL TO ASSESS THE SAFETY AND EFFICACY OF TRIPLETS FOR NEWLY DIAGNOSED UNFIT AML PATIENTS: AZACITIDINE OR LOW-DOSE CYTARABINE WITH VENETOCLAX AND QUIZARTINIB
por: Miguel Bergua Burgues, Juan, et al.
Publicado: (2023)

S128: AML CONDITIONING OF THE BONE MARROW MICROENVIRONMENT THROUGH CCR1 LIGAND UP-REGULATION PROMOTES AML STEM CELL PROPAGATION AND IS MIMICKED BY AGEING
por: Ren, Xiying, et al.
Publicado: (2023)

P531: MIDOSTAURIN PLUS 7 + 3 OR QUIZARTINIB PLUS 7 + 3 IN FLT3-ITD MUTATED AML
por: Tormo, Mar, et al.
Publicado: (2023)

Resistance Prediction in AML: Analysis of 4,601 Patients from MRC/NCRI, HOVON/SAKK, SWOG, and MD Anderson Cancer Center
por: Walter, Roland B., et al.
Publicado: (2014)

PU.1 downregulation in murine radiation-induced acute myeloid leukaemia (AML): from molecular mechanism to human AML
por: Verbiest, Tom, et al.
Publicado: (2015)

Sweet’s Syndrome (SS) in the Course of Acute Myeloid Leukaemia (AML)
por: Guarneri, Claudio, et al.
Publicado: (2018)

Randomized evaluation of quizartinib and low-dose ara-C vs low-dose ara-C in older acute myeloid leukemia patients
por: Dennis, Mike, et al.
Publicado: (2021)

Use of an anti‐CD200‐blocking antibody improves immune responses to AML in vitro and in vivo
por: Rastogi, Namrata, et al.
Publicado: (2020)

Immunophenotypic characterisation of morphologically diagnosed cases of Acute Myeloid Leukaemia (AML)
por: Basharat, Maria, et al.
Publicado: (2019)

S125: NON-GENETIC RESISTANCE TO MENIN INHIBITION IN AML IS REVERSIBLE BY PERTURBATION OF KAT6A
por: Perner, Florian, et al.
Publicado: (2023)

S130: NPM1 MUTATED AML: IMPACT OF CO-MUTATIONAL PATTERNS - RESULTS OF THE EUROPEAN HARMONY ALLIANCE
por: Hernández-Sánchez, A., et al.
Publicado: (2022)

Transcriptomic and proteomic analysis of mouse radiation-induced acute myeloid leukaemia (AML)
por: Badie, Christophe, et al.
Publicado: (2016)

Q-HAM: a multicenter upfront randomized phase II trial of quizartinib and high-dose Ara-C plus mitoxantrone in relapsed/refractory AML with FLT3-ITD
por: Jaramillo, Sonia, et al.
Publicado: (2023)

Combating drug resistance in acute myeloid leukaemia by drug rotations: the effects of quizartinib and pexidartinib
por: Yang, Jingmei, et al.
Publicado: (2021)

Outcomes of older patients aged 60 to 70 years undergoing reduced intensity transplant for acute myeloblastic leukemia: results of the NCRI acute myeloid leukemia 16 trial
por: Russell, Nigel H., et al.
Publicado: (2021)

Protein Kinase C Epsilon Overexpression Is Associated With Poor Patient Outcomes in AML and Promotes Daunorubicin Resistance Through p-Glycoprotein-Mediated Drug Efflux
por: Nicholson, Rachael, et al.
Publicado: (2022)

Outcomes with sequential FLT3-inhibitor-based therapies in patients with AML
por: Yilmaz, Musa, et al.
Publicado: (2020)

The Proteasome Inhibitor Bortezomib Sensitizes AML with Myelomonocytic Differentiation to TRAIL Mediated Apoptosis
por: van Dijk, Marianne, et al.
Publicado: (2011)

HCK maintains the self-renewal of leukaemia stem cells via CDK6 in AML
por: Li, Zheng, et al.
Publicado: (2021)

The epidemiology, treatment patterns, healthcare utilizations and costs of Acute Myeloid Leukaemia (AML) in Taiwan
por: Huang, Huai-Hsuan, et al.
Publicado: (2022)

Psychotropic Drug Use in Acute Myeloid Leukaemia (AML) and Myelodysplastic Syndrome (MDS): A Danish Nationwide Matched Cohort Study of 2404 AML and 1307 MDS Patients
por: Jensen, Oda, et al.
Publicado: (2022)

AML1/ETO Oncoprotein Is Directed to AML1 Binding Regions and Co-Localizes with AML1 and HEB on Its Targets
por: Gardini, Alessandro, et al.
Publicado: (2008)

Correction to: Outcomes with sequential FLT3-inhibitor-based therapies in patients with AML
por: Yilmaz, Musa, et al.
Publicado: (2021)

Effect of Food on the Pharmacokinetics of Quizartinib
por: Li, Jianke, et al.
Publicado: (2020)

The role of the proteasome in AML
por: Csizmar, C M, et al.
Publicado: (2016)

Maintenance Therapy in AML
por: Reville, Patrick K., et al.
Publicado: (2021)

A case of chronic myeloid leukaemia presenting as megakaryocytic blast crisis (AML M7)
por: Karkuzhali, Ponnuswamy, et al.
Publicado: (2013)

Reversal of MYB-dependent suppression of MAFB expression overrides leukaemia phenotype in MLL-rearranged AML
por: Negri, A., et al.
Publicado: (2023)

CALCRL Gene is a Suitable Prognostic Factor in AML/ETO(+) AML Patients
por: Wang, Rongrong, et al.
Publicado: (2022)

Autologous Transplantation for Older Adults with AML
por: Mueller, Beatrice U., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_5de70ob7dccmri0ajcaiinoca7